The Latin America, Middle East and Africa Sickle Cell Disease Treatment Market would witness market growth of 31.7% CAGR during the forecast period (2023-2030).
The market has been growing due to developments in treating anemia. Advancements have significantly influenced the market development for treating sickle cell disease in medicine and healthcare. Therefore, it is crucial to maintain the quantity and quality of hemoglobin in the blood. Recently, there has been an explosive increase in demand for sickle cell disease treatment.
The market has been developing along with the need to address disorders involving blood plasma. Sickle cell disease must be treated because hemoglobin deficiency can contribute to multiple bodily disorders. For patients with low hemoglobin levels, medical professionals advise prompt treatment methods. In the coming years, it is anticipated that this aspect will cause the market to increase more quickly. The market's expansion is also expected to be fuelled by rising per-capita healthcare costs and increased financing for logistical services.
Sickle cell disease is widespread in much of sub-Saharan Africa and affects a sizable percentage of births in several regions of the continent. The most prevalent form of SCD is SS disease, which occurs by homozygosity for the β-globin S gene mutation. Thus, because of the increasing number of screening and testing being conducted in the region, a significant proportion of the population is now aware about the impact of SCD. Such factors are aiding in the increasing demand for SCD treatment in the region.
The Brazil market dominated the LAMEA Sickle Cell Disease Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $120.2 Million by 2030. The Argentina market is showcasing a CAGR of 32.4% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 31.4% during (2023 - 2030).
Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Sickle Cell Disease Treatment Market is Projected to reach USD 7.3 Billion by 2030, at a CAGR of 27.9%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Treatment
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
By End-Use
- Hospitals
- Specialty Clinics
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer Inc.
- bluebird bio, Inc.
- CSL Limited
- Emmaus Life Sciences, Inc.
- Bristol Myers Squibb Company
- CRISPR Therapeutics AG
- Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
- Novo Nordisk A/S
- Medunik USA (Duchesnay Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Sickle Cell Disease Treatment Market, by Treatment
1.4.2 LAMEA Sickle Cell Disease Treatment Market, by End-Use
1.4.3 LAMEA Sickle Cell Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. LAMEA Sickle Cell Disease Treatment Market by Treatment
5.1 LAMEA Blood Transfusion Market by Country
5.2 LAMEA Pharmacotherapy Market by Country
5.3 LAMEA Bone Marrow Transplant Market by Country
Chapter 6. LAMEA Sickle Cell Disease Treatment Market by End-use
6.1 LAMEA Hospitals Market by Country
6.2 LAMEA Specialty Clinics Market by Country
6.3 LAMEA Others Market by Country
Chapter 7. LAMEA Sickle Cell Disease Treatment Market by Country
7.1 Brazil Sickle Cell Disease Treatment Market
7.1.1 Brazil Sickle Cell Disease Treatment Market by Treatment
7.1.2 Brazil Sickle Cell Disease Treatment Market by End-use
7.2 Argentina Sickle Cell Disease Treatment Market
7.2.1 Argentina Sickle Cell Disease Treatment Market by Treatment
7.2.2 Argentina Sickle Cell Disease Treatment Market by End-use
7.3 UAE Sickle Cell Disease Treatment Market
7.3.1 UAE Sickle Cell Disease Treatment Market by Treatment
7.3.2 UAE Sickle Cell Disease Treatment Market by End-use
7.4 Saudi Arabia Sickle Cell Disease Treatment Market
7.4.1 Saudi Arabia Sickle Cell Disease Treatment Market by Treatment
7.4.2 Saudi Arabia Sickle Cell Disease Treatment Market by End-use
7.5 South Africa Sickle Cell Disease Treatment Market
7.5.1 South Africa Sickle Cell Disease Treatment Market by Treatment
7.5.2 South Africa Sickle Cell Disease Treatment Market by End-use
7.6 Nigeria Sickle Cell Disease Treatment Market
7.6.1 Nigeria Sickle Cell Disease Treatment Market by Treatment
7.6.2 Nigeria Sickle Cell Disease Treatment Market by End-use
7.7 Rest of LAMEA Sickle Cell Disease Treatment Market
7.7.1 Rest of LAMEA Sickle Cell Disease Treatment Market by Treatment
7.7.2 Rest of LAMEA Sickle Cell Disease Treatment Market by End-use
Chapter 8. Company Profiles
8.1 bluebird bio, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.5 SWOT Analysis
8.2 CRISPR Therapeutics AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.5 SWOT Analysis
8.3 Agios Pharmaceuticals, Inc. (Les Laboratoires Servier SAS)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.3.4 Recent strategies and developments:
8.3.4.1 Trials and Approvals:
8.3.5 SWOT Analysis
8.4 Medunik USA (Duchesnay Inc.)
8.4.1 Company Overview
8.4.2 Recent strategies and developments:
8.4.2.1 Trials and Approvals:
8.4.3 SWOT Analysis
8.5 CSL Limited
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental & Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Trials and Approvals:
8.7.6 SWOT Analysis
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. Emmaus Life Sciences, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Product Launches and Product Expansions:
8.10.4.3 Trials and Approvals:
8.10.5 SWOT Analysis
TABLE 1 LAMEA Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Sickle Cell Disease Treatment Market
TABLE 4 Product Launches And Product Expansions– Sickle Cell Disease Treatment Market
TABLE 5 Acquisition and Mergers– Sickle Cell Disease Treatment Market
TABLE 6 Trials and Approvals- SICKLE Cell Disease Treatment Market
TABLE 7 LAMEA Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 8 LAMEA Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 9 LAMEA Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 LAMEA Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 13 LAMEA Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 16 LAMEA Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 17 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 19 LAMEA Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 21 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 22 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 23 LAMEA Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 25 Brazil Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 26 Brazil Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 27 Brazil Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 28 Brazil Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 29 Brazil Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 30 Brazil Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 31 Argentina Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 32 Argentina Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 33 Argentina Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 34 Argentina Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 35 Argentina Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 36 Argentina Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 37 UAE Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 38 UAE Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 39 UAE Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 40 UAE Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 41 UAE Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 42 UAE Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 43 Saudi Arabia Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 44 Saudi Arabia Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 45 Saudi Arabia Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 46 Saudi Arabia Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 47 Saudi Arabia Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 48 Saudi Arabia Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 49 South Africa Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 50 South Africa Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 51 South Africa Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 52 South Africa Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 53 South Africa Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 54 South Africa Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 55 Nigeria Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 56 Nigeria Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 57 Nigeria Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 58 Nigeria Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 59 Nigeria Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 60 Nigeria Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 61 Rest of LAMEA Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 62 Rest of LAMEA Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 63 Rest of LAMEA Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 64 Rest of LAMEA Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 65 Rest of LAMEA Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 66 Rest of LAMEA Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 67 Key Information – bluebird bio, Inc.
TABLE 68 Key Information – CRISPR Therapeutics AG
TABLE 69 Key Information – Agios Pharmaceuticals, Inc.
TABLE 70 Key Information – Medunik USA
TABLE 71 Key Information – CSL Limited
TABLE 72 Key Information – Novo Nordisk A/S
TABLE 73 Key Information – Novartis AG
TABLE 74 Key Information – Pfizer, Inc.
TABLE 75 Key Information – Bristol Myers Squibb Company
TABLE 76 Key Information – Emmaus Life Sciences, INC.
List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Sickle Cell Disease Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Sickle Cell Disease Treatment Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Sickle Cell Disease Treatment Market
FIG 8 LAMEA Sickle Cell Disease Treatment Market share by Treatment, 2022
FIG 9 LAMEA Sickle Cell Disease Treatment Market share by Treatment, 2030
FIG 10 LAMEA Sickle Cell Disease Treatment Market by Treatment, 2019 - 2030, USD Million
FIG 11 LAMEA Sickle Cell Disease Treatment Market share by End-use, 2022
FIG 12 LAMEA Sickle Cell Disease Treatment Market share by End-use, 2030
FIG 13 LAMEA Sickle Cell Disease Treatment Market by End-use, 2019 - 2030, USD Million
FIG 14 LAMEA Sickle Cell Disease Treatment Market share by Country, 2022
FIG 15 LAMEA Sickle Cell Disease Treatment Market share by Country, 2030
FIG 16 LAMEA Sickle Cell Disease Treatment Market by Country, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: bluebird bio, Inc.
FIG 18 SWOT Analysis: CRISPR Therapeutics AG
FIG 19 SWOT Analysis: Agios Pharmaceuticals, Inc.
FIG 20 SWOT Analysis: Medunik USA
FIG 21 SWOT Analysis: CSL Limited
FIG 22 SWOT Analysis: Novo Nordisk A/S
FIG 23 Recent strategies and developments: Novartis AG
FIG 24 SWOT Analysis: Novartis AG
FIG 25 SWOT Analysis: Pfizer, Inc.
FIG 26 SWOT Analysis: Bristol Myers Squibb Company
FIG 27 Recent strategies and developments: Emmaus Life Sciences, Inc.
FIG 28 SWOT Analysis: Emmaus Life Sciences, Inc.